دورية
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial
| العنوان: | First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial |
|---|---|
| المؤلفون: | Joly, Pascal, Maho-Vaillant, Maud, Prost-Squarcioni, Catherine, Hebert, Vivien, Houivet, Estelle, Calbo, Sébastien, Caillot, Frédérique, Golinski, Marie Laure, Labeille, Bruno, Picard-Dahan, Catherine, Paul, Carle, Richard, Marie-Aleth, Bouaziz, Jean David, Duvert-Lehembre, Sophie, Bernard, Philippe, Caux, Frederic, Alexandre, Marina, Ingen-Housz-Oro, Saskia, Vabres, Pierre, Delaporte, Emmanuel, Quereux, Gaelle, Dupuy, Alain, Debarbieux, Sebastien, Avenel-Audran, Martine, D'Incan, Michel, Bedane, Christophe, Bénéton, Nathalie, Jullien, Denis, Dupin, Nicolas, Misery, Laurent, Machet, Laurent, Beylot-Barry, Marie, Dereure, Olivier, Sassolas, Bruno, Vermeulin, Thomas, Benichou, Jacques, Musette, Philippe |
| المصدر: | The Lancet; May 2017, Vol. 389 Issue: 10083 p2031-2040, 10p |
| مستخلص: | High doses of corticosteroids are considered the standard treatment for pemphigus. Because long-term corticosteroid treatment can cause severe and even life-threatening side-effects in patients with this disease, we assessed whether first-line use of rituximab as adjuvant therapy could improve the proportion of patients achieving complete remission off-therapy, compared with corticosteroid treatment alone, while decreasing treatment side-effects of corticosteroids. |
| قاعدة البيانات: | Supplemental Index |
| تدمد: | 01406736 1474547X |
|---|---|
| DOI: | 10.1016/S0140-6736(17)30070-3 |